Dr. Tilley is a Partner at CTI Life Sciences Fund, L.P. Prior to joining CTI, Dr. Tilley was a Senior Vice President at Drug Royalty Corporation, a Bay Street private equity firm focused on biopharmaceutical investment. While at DRC she managed the due diligence and analysis group, and participated in transactions totaling over $200M. Before DRC, Dr. Tilley held faculty and research positions at the NYU School of Medicine and the Public Health Research Institute (PHRI), New York, and served on the PHRI Board of Directors. Concomitantly with her tenure at NYU School of Medicine and PHRI, she consulted for the National Institutes of Health Small Business Innovation Research (SBIR) program.